Risk Factor | Univariate analysis | Multivariable analysisa | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PFS | OS | PFS | OS | |||||||||
HR | 95 % CI | P | HR | 95 % CI | P | HR | 95 % CI | P | HR | 95 % CI | P | |
Prior capecitabine vs. no prior capecitabine | 1.50 | 1.12-2.02 | 0.0072 | 1.33 | 0.97-1.83 | 0.0790 | 1.22 | 0.89-1.67 | 0.2140 | 0.73 | 0.48-1.10 | 0.1351 |
Hormone receptor positive vs. hormone receptor negative | 0.78 | 0.57-1.06 | 0.1064 | 0.80 | 0.57-1.11 | 0.1741 | ||||||
Best systemic response SD, PD vs. CR, PR | 2.54 | 1.85-3.48 | <0.0001 | 1.88 | 1.33-2.64 | 0.0003 | 2.60 | 1.87-3.63 | <0.0001 | 1.31 | 0.86-1.99 | 0.2064 |
Median prior trastuzumab duration, wks ≥24.1 vs. <24.1 | 0.68 | 0.50-0.91 | 0.0108 | 0.57 | 0.41-0.78 | 0.0006 | 0.66 | 0.48-0.89 | 0.0074 | 0.68 | 0.48-0.96 | 0.0271 |
Age ≥50 vs. <50 | 0.89 | 0.66-1.20 | 0.4418 | 0.84 | 0.61-1.15 | 0.2726 | ||||||
No. of metastasis ≥3 vs. <3 | 1.16 | 0.86-1.16 | 0.3427 | 1.64 | 1.18-2.28 | 0.0034 | 1.78 | 1.23-2.58 | 0.0023 | |||
No. of prior chemotherapy regimens >3 vs. ≤3 | 1.17 | 0.86-1.58 | 0.3214 | 1.58 | 1.14-2.19 | 0.0067 | 1.64 | 1.08-2.47 | 0.0194 | |||
Pattern of metastasis Visceral only vs. other | 1.58 | 1.17-2.15 | 0.0031 | 0.98 | 0.70-1.36 | 0.8928 | 1.61 | 1.18-2.21 | 0.0031 | |||
Median TTP, wks ≥20.0 vs. <20.0 | 0.36 | 0.26-0.50 | <0.0001 | 0.37 | 0.25-0.56 | <0.0001 | ||||||
Brain metastasis vs. no brain metastasis | 0.98 | 0.71-1.35 | 0.8979 | 1.23 | 0.88-1.74 | 0.2310 |